Begin first-in-human study for COR588
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 26 Jan 2021
- Due
- 30 Sep 2021
- Delivered
- August 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“a first-in-human study is expected to begin in Q3 2021”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 1 first-in-human study for COR588 in August 2021, which is within the third quarter of 2021.
-
A Cortexyme, Inc. 10-K filed 2022-03-01
“We began a Phase 1 SAD/MAD trial of COR588 in a cohort of healthy participants in Australia in August 2021” ✓ confirmed on the page
Market reaction: the shares moved -0.9% against the S&P 500 over the three sessions around the disclosure (28 Feb 2022 to 3 Mar 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- COR588 first-in-human study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Cortexyme, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IRLA-022417 · Corrections policy